Aflibercept sustained release - Regeneron/Ocular Therapeutix

Drug Profile

Aflibercept sustained release - Regeneron/Ocular Therapeutix

Alternative Names: Aflibercept punctal plug - Regeneron/Ocular Therapeutix; OTX IVT

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocular Therapeutix; Regeneron Pharmaceuticals
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 23 Oct 2017 Preclinical trials in Diabetic macular oedema in USA before October 2017 (Intravitreous) (Ocular Therapeutix pipeline, October 2017)
  • 13 Oct 2016 Regeneron and Ocular Therapeutix collaborate on the development of Aflibercept sustained release and other therapeutics for Retinal disorders
  • 13 Oct 2016 Preclinical trials in Retinal vein occlusion in USA (Intravitreous) (Ocular Therapeutix pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top